Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-05-24
2005-05-24
LeGuyader, John L. (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C530S300000, C530S350000, C530S387100, C536S023100, C536S024500
Reexamination Certificate
active
06897019
ABSTRACT:
The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and/or an inhibitor of the MAPK/ERK signal transduction pathway.
REFERENCES:
patent: 5405941 (1995-04-01), Johnson
patent: 5459036 (1995-10-01), Lechner et al.
patent: 5534426 (1996-07-01), Karin et al.
patent: 5593884 (1997-01-01), Karin et al.
patent: 5595904 (1997-01-01), Boulton et al.
patent: 5605808 (1997-02-01), Karin et al.
patent: 5663313 (1997-09-01), Hawkins et al.
patent: 5663314 (1997-09-01), Seger et al.
patent: 5708012 (1998-01-01), Olefsky
patent: 5712265 (1998-01-01), Cincotta et al.
patent: 5712283 (1998-01-01), Kaan et al.
patent: 5730975 (1998-03-01), Hotamisligil
patent: 5804399 (1998-09-01), Karin et al.
patent: 5837244 (1998-11-01), Karin et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5994513 (1999-11-01), Karin et al.
patent: 6001584 (1999-12-01), Karin et al.
patent: 6110948 (2000-08-01), Momose et al.
patent: 6193965 (2001-02-01), Karin et al.
patent: 6255059 (2001-07-01), Klein et al.
patent: 6342595 (2002-01-01), Karin et al.
patent: 6514745 (2003-02-01), Karin et al.
patent: WO 9423039 (1994-10-01), None
patent: WO 9521923 (1995-08-01), None
patent: WO 9636642 (1996-11-01), None
patent: WO 9702347 (1997-01-01), None
patent: WO 9706245 (1997-02-01), None
L G D Fryer et al., Selective modification of insulin action in adipose tissue by hyperthyroidism, Journal of Endocrinology (1997) 154 pp. 513-522.*
W. Michael Flanagan et al., Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide, RESEARCH.*
Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23—Feb. 1998, pp. 45-50.*
Ricote, M. et al. (1998), The Peroxisome Proliferator-Activated Receptor-γ is a Negative Regulator of Macrophage Activation,Nature391:79.
Jiang, C. et al. (1998), PPAR-γ Agonists Inhibit Production of Monocyte Inflammatory Cytokines,Nature391:82.
Shepard, P. et al. (1999), Glucose Transporters and Insulin Action,New Eng. J. of Med.341(4):248.
Knopp, R. (1999), Drug Treatment of Lipid Disorders,New Eng. J. of Med.341(7):498.
Suga, J. et al. (1997), Differential Activation of Mitoge-Activated Protein Kinase by Insulin and Epidermal Growth Factor in 3T3-L1 Adipocytes,Diabetes46:735.
Hotamisligil, G. et al. (1994), Reduced Tyrosine Kinase Activity of the Insulin Receptor in Obesity-Diabetes,J. Clin. Invest.94:1543.
Kim, S. et al. (1997), Insulin Regulation of Mitogen-Activated Protein Kinase Kinase (MEK), Mitogen-Activated Protein Kinase and Casoin Kinase in the Cell Nucleus: A Possible Role in the Regulation of the Gene Expression,Biochem J.323:621.
Souza, S. et al. (1998), BRL 49653 Blocks the Lipolytic Actions of Tumor Necrosis Factor-α,Diabetes47:691.
Souza, S. et al. (1997), Salicylic Acid Decreases the Ability of Tumor Necrosis Factor (TNF-α) to Increase Lipolysis in 313-L1 Adipocytes,FASEB J.11(3):919.
Wang, C. et al. (1998), Effects of Cell-Permeable Ceramides and Tumor Necrosis Factor-α on Insulin Signaling and Glucose Uptake in 313-L1 Adipocytes,Diabetes47:24.
Hu, E. et al. (1996), Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylationh of PPARγ,Science274:2100.
Biomol Research News (1997), Antisense Reagents, 6(1).
Rizzo, M. et al. (1996), Arachidonic Acid Mediates Interleukin-1 and Tumor Necrosis Factor-α-Induced Activation of the c-jun Amino Terminal Kinases in Stromal Cells,Blood88(10):3792.
Robertson, R.P. (1988), Eicosanoids as Pluripotential Modulators of Pancreatic Islet Function,Diabetes37:367.
Tebbey, P. et al. (1994), Arachidonic Acid Down-Regulates the Insulin-Dependent Glucose Transporter Gene (GLUT4) in 3T3-L1 Adipocytes by Inhibiting Transcription and Enhancing mRNA Turnover,J. Bio. Chem.269(1):639.
Feinstein, R. et al. (1993), Tumor Necrosis Factor-α Suppresses Insulin-Induced Tyrosine Phosphorylation of Insulin Receptor and its Substrates,J. Bio. Chem.268(35):26055.
Lehmann, J. et al. (1995), An Antidiabetic Thiazolidinedione is a High Affinity Ligend for Peroxisome Proliferator-Activated Receptor γ (PPARγ),J. Bio. Chem.270(22):12953.
Ibrahimi, A. et al. (1994), Evidence for a Common Mechanism of Action for Fatty Acids and Thiazolidinedione Antidiabetic Agents on Gene Expression in Preadipose Cells,Molecular Pharmacology46:1070.
Cobb, M.H. et al. (1995), How MAP Kinases are Regulated,J. Bio. Chem.270(25):14843.
Liu, Z. et al. (1996), Dissection of TNF Receptor 1 Effector Functions: JNK Activation is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death,Cell87:565.
Oakes, N. et al (1994), A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat,Diabetes43:203.
Vane, J.R. (1971), Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs,Nature New Bio.231:232.
Kyriakis, J.M. et al. (1994), The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases,Nature369:156.
Vossler, M.R. et al. (1997), cAMP Activates MAP Kinase and Elk-1 Through a B-Raf- and Rap1-Dependent Pathway,Cell89:73.
Feingold. K.R. et al. (1992), Stimulation of Lipolysis in Cultured Fat Cells by Tumor Necrosis Factor, Interleukin-1, and the Interferons is Blocked by Inhibition of Prostaglandin Synthesis,Endo130(1):10.
Hotamisligil, G.S. et al. (1995), Increased Adipose Tissue Expression of Tumor Necrosis Factor-αin Human Obesity and Insulin Resistance,J. Clin. Invest.95:2409.
Kern, P.A. et al (1995), The Expression of Tumor Necrosis Factor in Human Adipose Tissue,J. Clin. Invest.95:2111.
Roden, M. et al. (1996), Mechanism of Free Fatty Acid-Induced Insulin Resistance in Humans,J. Clin. Invest.97(12):2859.
Smith, U. (1994), Carbohydrates, Fat, and Insulin Action,Am. J. Clin. Nutr.59:686S.
Nolan, J.J. et al. (1994), Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone,New Eng. J. of Med.331(18):1188.
Beutler, B. (1995), TNF, Immunity and Inflammatory Disease: Lessons of the Past Decade,J. Invest. Med.43(3):227.
Kroder, G. et al. (1996), Tumor Necrosis Factor-α-and Hyperglycemia-Induced Insulin Resistance,J. Clin. Invest.97(6):1471.
Hardardottir, I. et al. (1992), Cytokines Stimulate Lipolysis and Decrease Lipoprotein Lipase Activity in Cultured Fat Cells by a Prostaglandin Independent Mechanism,Biochem. And Biophys. Res. Comm.186(1): 237.
Zhang, C. et al. (1997), Mitogen-Activated Protein (MAP) Kinase Regulates Production of Tumor Necrosis Factor-α and Release of Arachidonic Acid in Mast Cells,J. Bio. Chem.272(20):13397.
Lehmann. J.M. et al. (1997), Peroxisome Proliferator-Activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs,J. Bio. Chem.272(6):3406.
Boden, G. (1997), Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM,Diabetes46:3.
Reaven, G.M. (1988), Role of Insulin Resistance in Human Disease,Diabetes37:1595.
Hotamisligil, G.S. et al (1994), Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link,Diabetes43:1271.
Dunaif, A. et al. (1996), The Insulin Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome,J. Clin. Endocrinology and Metabolism81(9):3299.
Davis, R.J. (1994), MAPKs: New JNK Expands the Group,TIBS19:470.
Long, S.D. (1996), Regulation of GLUT4 Gene Expression by Arachidonic Acid,J. Bio. Chem.271(2):1138.
Tebbey, P.W. (1994), Arachidonic Acid Down-Regulates the Insulin-Dependent Glucose Transporter Gene (GLUT4) in 3T3-L1 Adipocytes by
LeGuyader John L.
Schultz J D
LandOfFree
Methods for treating and preventing insulin resistance and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating and preventing insulin resistance and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating and preventing insulin resistance and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460290